Abstract | OBJECTIVES: METHODS: RESULTS: Nine patients had circulating tumor deoxyribonucleic acid in pretreatment plasma samples with a total of 20 mutations (15 single nucleotide variants, three insertions/deletions, and two copy number amplification). VHL (30.0%) was the most frequently mutated gene, followed by TP53 (20.0%), and 45.0% of circulating tumor deoxyribonucleic acid mutations were concordant with somatic mutations in tumor tissues. Patients with decreasing circulating tumor deoxyribonucleic acid mutant allele frequency had better progression free survival when compared to those with increasing mutant allele frequency (P = 0.0441). CONCLUSIONS:
|
Authors | Yoko Koh, Kosuke Nakano, Kotoe Katayama, Gaku Yamamichi, Satoru Yumiba, Eisuke Tomiyama, Makoto Matsushita, Yujiro Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Ryoichi Imamura, Rui Yamaguchi, Seiya Imoto, Yukimasa Shiotsu, Norio Nonomura, Motohide Uemura |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 29
Issue 5
Pg. 462-469
(05 2022)
ISSN: 1442-2042 [Electronic] Australia |
PMID | 35184335
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. |
Chemical References |
- Biomarkers, Tumor
- Circulating Tumor DNA
- Immune Checkpoint Inhibitors
- Nivolumab
|
Topics |
- Biomarkers, Tumor
(genetics)
- Carcinoma, Renal Cell
(drug therapy, genetics, secondary)
- Circulating Tumor DNA
(genetics)
- Female
- Humans
- Immune Checkpoint Inhibitors
(pharmacology, therapeutic use)
- Kidney Neoplasms
(drug therapy, genetics, pathology)
- Male
- Nivolumab
(therapeutic use)
|